Aspira is Transforming Women's Health

with Innovative Solutions

Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.

Meet our Leadership Team

About Aspira Women's Health

Our Mission

Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products OVA1® and OVERA® detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, Aspira GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.

Learn More

$0.6810 $0.1666 32.3872%

Most Recent Press Releases


  • Aspira Women’s Health Announces Appointment of Two New Board Members

    Seasoned Directors further strengthen Board with decades of industry and leadership experience June 23, 2022 16:05 ET AUSTIN, Texas, June 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the appointments of two seasoned Board members: Dr. Robert Auerbach and Ms. Ruby Sharma. Dr

  • Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer

    Paper published in the June online issue of JCO Clinical Cancer Informatics June 16, 2022 16:01 ET AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the online publication of a paper validating its OvaWatch™ algorithm in the detection of…

  • View all Press Releases